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Abstract 
Background: Pneumococcal disease is a transmitted infectious illness that results in serious 
complications and death every year in the United States.  Given their increased susceptibility to 
the potential complications of this disease, patients aged 65 and older are considered to be high-
risk, but vaccination compliance for this population remain well below state and national goals.  
Purpose: The purpose of this project was to increase pneumococcal vaccination rates among 
adults aged 65 and older in a primary care clinic by increasing patient education.   
Methods: An educational intervention was implemented within a large primary care practice 
located in Central Massachusetts.  Educational materials were distributed within the clinic, 
including posters, vaccine information sheets, and flyers.  Cumulative vaccination rates for 
pneumococcal pneumonia among the target population were analyzed pre and post intervention 
to evaluate project impact.  Mixed methods were used for analyzing project results.  
Results: Results demonstrated a nearly 10% increase in cumulative vaccination rates after project 
implementation.  There also proved a statistically significant relationship between patient 
education and rates of vaccination exists (p < .0001).  
Conclusion: The project’s findings demonstrate that increasing patient education in the primary 
care setting can improve rates of vaccination against pneumococcal pneumonia in vulnerable 
patient populations.  
 Keywords: pneumococcal, pneumonia, patient education, standing order programs, 
vaccination, immunization, barriers, older adults.   
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Introduction and Background 
Introduction 
Vaccines are arguably one of the most powerful medicines available to patients to prevent 
illness and reduce infectious disease morbidity and mortality.  The Centers for Disease Control 
and Prevention (CDC) (2014) recommends routine vaccinations from birth through adulthood to 
provide a lifetime of protection against vaccine preventable diseases.  Notable increase in 
average life expectancy during the last century is associated with decreased rates of infectious 
disease mortality attributable to vaccinations.  As one of the most cost-effective clinical 
preventive services, investment into vaccines yields a high return (U.S. Department of Health 
and Human Services [HHS], 2014).  Currently, the Advisory Committee on Immunization 
Practices (ACIP) recommends twelve different immunizations for adults ages 19 and older, 
including two specific to preventing pneumonia: Pneumococcal polysaccharide vaccine (PPSV-
23) and Pneumococcal conjugate vaccine (PCV-13) (CDC, 2015). 
Pneumococcal disease is an easily transmitted, significantly infectious illness that results 
in massive expense, complications and death every year in the U.S. (American Lung Association 
[ALA], 2010).  High-risk patients aged 65 and older are more susceptible to potential 
complications associated with pneumonia as it often exacerbates underlying illnesses.  Older 
individuals are more likely to experience respiratory failure, sepsis, lung abscesses or even death.  
Pneumococcal disease claims the lives of one in every four to five people over the age of 65 that 
contracts it and in 2013, was responsible for 53,282 deaths in the U.S.; together with influenza it 
is currently the fifth leading cause of death in the older adult (NFID, 2015).  Community- 
acquired pneumonia is responsible for 350,000-620,000 hospitalizations for older adults annually 
and survival rates among this population are lower than younger individuals; furthermore, those 
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who may survive the initial illness sustain a higher-than-normal morbidity rate in forthcoming 
years.  With the baby boomer generation aging, it is anticipated that disease incidence will rise 
proportionately.  The CDC (2011) has estimated that by the year 2030 the number of U.S. adults 
65 years and older will have doubled to approximately 71 million; simultaneously, life 
expectancy will continue to increase, introducing a greater opportunity for these diseases to 
wreak their havoc on society. 
Background 
Pneumococcal disease places a financial burden on the U.S.; in 2004 an estimated four 
million episodes of illness resulted in direct medical costs of $3.5 billion, half of which ($1.8 
billion) were related to care of patients aged 65 and older (Huang et al., 2011).  It is projected 
that pneumococcal pneumonia hospitalizations will increase by 96% between 2004 and 2040.  
Without intervention the increasing demand for healthcare services will double in coming 
decades, and the total cost of pneumococcal pneumonia will increase by $2.5 billion annually 
(Wroe et al., 2012).  However, approximately 70 million adults considered high-risk remain 
unvaccinated (CDC, 2013).  Healthy People 2020 maintains a target goal of a 90% vaccination 
rate for pneumonia in adults 65 years and older, but with current data exhibiting a suboptimal 
total of 59.7%, disparities in vaccination rates clearly exist (CDC, 2013; HHS, 2014). 
A multitude of factors contribute to whether an individual will seek medical treatment, 
including vaccination.  Health service or treatment must be perceived by the individual to be 
important, beneficial to their wellbeing, easily available and affordable (ALA, 2010).  From a 
global perspective, lack of resources and infrastructure play a large role in barring efforts to 
promote preventive care.  In certain developing countries, citizens struggle to pay for basic 
medical procedures and consider anything greater than basic a luxury (Pfizer, 2012).  Within the 
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U.S. issues pertaining to cost appear to be less concerning for patients than personal awareness or 
beliefs (ALA, 2010).  Reported barriers have also included a lack of awareness of the disease 
and/or vaccine, competing priorities, time restraints, incomplete or unobtainable immunization 
histories and delivery challenges within the health care system (Rehm et al., 2012).  With 
coverage levels not attaining nationwide goal, infectious disease still remains prevalent in society 
and there is a consequential need to develop, understand and promote interventions in primary 
care that will increase immunization rates.  This quality improvement DNP project investigated 
the feasibility of increased patient education having an impact on pneumococcal pneumonia 
vaccination rates among patients 65 and older in a primary care setting.   
Problem Statement 
Risk of serious health complications from pneumococcal pneumonia among U.S. patients’ 
ages 65 and older has been made evident by consistently high morbidity and mortality rates from 
vaccine preventable pneumococcal pneumonia related to suboptimal vaccination coverage 
resulting from a multitude of perceived personal and logistical barriers among patients and 
providers alike. 
Literature Review 
A search of the literature was conducted to identify and critique existing methods to 
improve pneumococcal vaccination rates among patients aged 65 years and older.  The review 
further sought to identify patient and provider perceived barriers to immunization.   
Standing Orders Program 
Standing orders programs (SOP) as recommended by the ACIP allow non-provider 
personnel to assess the vaccination status of patients and administer vaccines without an 
individual physician order.  An outline of the ACIP’s report on their recommendations is 
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available to review in Appendix A.  The Immunization Action Coalition (2014) has developed a 
multitude of SOPs allowing eligible staff (i.e. nurses and pharmacists) within approved states the 
autonomy to identify and subsequently vaccinate individuals that meet specified criteria; 
standing orders already exist for both pneumococcal vaccines (PPSV23 and PCV13) with an 
ultimate goal of reducing overall morbidity and mortality from pneumococcal disease.  A copy 
of the existing orders protocol is provided in Appendix B.  The review specifically identifies 
current evidence within the literature pertaining to SOPs, including barriers to implementation 
and successes achieved when said barriers are eliminated. 
Methods 
The initial search included the following databases: PubMed and Google Scholar.  Prior 
to undergoing the search, texts published by experts in systematic reviews were utilized for 
reference on database selection and search term development.  Medical Subject Headings 
(MeSH) terms included a varying combination of the following: pneumococcal, pneumonia, 
vaccination, immunization, rates, improving, interventions, and older adults.  Two additional 
terms were later included to further expand the search: standing order programs and SOP.  After 
an initial review was undergone, the DNP student chose to isolate and explore literature 
pertaining specifically to the interventional use of Standing Order Programs (SOP) and the 
benefits increased patient education has on increasing vaccination rates. 
Inclusion criteria consisted of full-text articles published in the English language within 
the past 5 years (2010-2015).  Retrospectively, a larger time span may have been beneficial as 
there were limited publications available.  Articles were filtered to focus on the community 
setting in order to maximize primary care relevance.  Those non-specific to adults 65 years of 
age and older were used sparingly but not omitted, as some provided high-quality analysis of 
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SOP implementation.  Studies focusing on interventions other than standing order programs were 
not evaluated, unless the intervention was used in combination with a standing order.  Initial 
search yielded 482 articles, which were further delineated into 15 sources, each scrutinized 
according to specific criteria of reliability, validity and applicability to future research and 
practice scenarios.  Nine articles were chosen for final synthesis and major patterns and gaps 
across the literature pertaining to this possible intervention were identified. 
Results and Synthesis of the Evidence 
The Johns Hopkins Nursing Evidence-based Practice Rating Scale (JHNEBP) was 
utilized to assess methodological quality of the literature.  For the quantitative studies, 
internal/external validity and reliability were taken into account, while credibility, transferability 
and generalizability were considered in reviewing the qualitative. 
Benefits to Vaccination.  Multiple studies have validated the claim that vaccination 
against pneumonia will decrease risk for potential complications (CDC, 2015).  In a study of 
approximately 85,000 adults 65 years and older in the Netherlands, researchers found PCV-13 
was effective at preventing invasive pneumococcal disease and 45% effective at preventing 
pneumococcal pneumonia (Mangen et al., 2015).  Bonten et al. (2015) conducted a similar study 
among 84,496 adults within the United States in which one group was vaccinated and the other 
was not.  Just as in the study by Mangen et al., researchers identified a positive correlation 
between pneumococcal vaccination and rates of illness: Community-acquired pneumonia was 
diagnosed in 49 vaccinated individuals versus 90 in the unvaccinated placebo group (vaccine 
efficacy, 45.6%; 95.2% CI, 21.8 to 62.5); invasive pneumococcal disease was recognized in 7 
individuals of the PCV13 group and 28 in the placebo (75.0%, 95% CI, 41.4 to 90.8).  Both 
studies demonstrate that pneumococcal vaccination is effective in preventing disease.  
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A single dose of PPSV-23 is recommended routinely for adults 65 and older as an 
effective means of preventing invasive pneumococcal disease (ACIP, 2010).  However, data on 
the vaccine’s effectiveness against community-acquired pneumonia is inconsistent and various 
studies have been unable to provide adequate evidence proving PPSV-23 effective against non-
invasive pneumococcal pneumonia (NPP) among older adults in the community (Huss et al., 
2009; Moberly, Holden, Tatham & Andrews, 2008).  The addition of PCV-13 into the older adult 
population is predicted to improve coverage against this type of pneumonia and studies are being 
undergone for further exploration (Smith et al., 2012).  Currently, the ACIP recommends 
immunocompetent older adults receive both vaccines as a way to broaden their coverage against 
varying strains of pneumonia.  Patients 65 and older that have previously been vaccinated with 
PPSV-23 should receive a single dose of PCV-13 at least one year after having received the 
PPSV23.  For those adults 65 and older that have not received either pneumococcal vaccination, 
a single dose of PCV-13 should be given first, followed by a dose of PPSV-23 six to twelve 
months later. 
Efficacy of Standing Order Protocol Use.  Current literature suggests use of SOPs as an 
effective means of raising rates of vaccinations (Appel, 2011).  The United States Preventive 
Services Task Force (USPSTF) recommends the use of SOPs as a highly graded preventive tool 
and members of the American Academy of Family Physicians (AAFP) further support belief in 
SOP efficacy.  Evidence demonstrates a direct correlation exists between implementation of an 
SOP and increased vaccination rates (Albert et al., 2012; Bardenheier et al., 2010; Nowalk et al., 
2014; Zimmerman et al., 2011).  Nowalk et al. (2014) conducted an observational study among 
providers from four diverse primary care practices (Level II, Grade B).  Utilizing group 
interviews and surveys as reliable tools to measure outcomes, researchers implemented use of an 
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SOP toolkit and found PPSV rates of high-risk adult patients increased from 25% to 40% in just 
one year.  Results of the study indicated minimal effect on the older adult population, revealing 
inconsistency in the study’s findings.  However, influenza vaccination rates exhibited significant 
improvement in three out of four sites overall (22% vs.33%, p < .001), justifying the researchers’ 
claims of SOPs positively impacting rates of vaccination.  
Similarly, Bardenheier, Shefer, Lu, Remsburg and Marstellar (2010) also yielded positive 
results from their cross-sectional study of a randomized sample of 11,939 nursing home residents 
65 years and older (Level I, Grade A).  Aiming to assess the impact of SOPs vs. alternative 
programs on influenza vaccination rates, the researcher identified a positive relationship between 
use of standing orders and greater vaccination coverage (66.7% versus 62.0%, respectively, P < 
.01).  In congruence with the previous study’s conclusions, Middleton et al. (2008) also proved 
that utilization of an SOP is a cost-effective method for increasing rates of pneumococcal 
vaccination among hospitalized elderly patients.  Newly admitted patients to a 1,094 bed tertiary-
care hospital were screened for PPSV eligibility and then offered the vaccine resulting in overall 
vaccination rates increased by 30.5%.  More research will be beneficial in analyzing the impact 
of SOPs on alternative outpatient locations.   
In continued support of the previous findings, Smith and Metzger (2011) conducted an 
experimental pre-test/post-test study among 300 randomly selected adult patients of two separate 
Internal Medicine units.  The sample was isolated into two groups of 150 patients with the 
purpose to determine if a multifaceted vaccine protocol inclusive of standing orders would 
increase rates of screening and vaccination among eligible patients.  The overall screening rate 
was similar between both pre and post-implementation groups (96% vs. 93%).  However, the 
rate of vaccination was significantly different (19.1% to 74.2%, respectively).  Within their 
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analysis, researchers highlighted findings from a prospective, randomized controlled study 
conducted by Dexter et al. (2004) in which patients designated to an electronic standing order 
group had higher rates of vaccination against pneumonia opposed to a group using electronic 
reminders as an intervention (51% vs. 31%, respectively, p <0.001).  Methods of measurements 
for both studies were reliable and data successfully demonstrate noteworthy findings consistent 
with previous studies included in this review: Standing order programs are an effective method 
of increasing vaccination rates.  
Correlates of SOP Use.  Despite proven benefit to increasing vaccination rates, 
consistent underutilization of SOPs signifies barriers exist to implementation.  In a nationally 
represented sample of 880 physicians, Albert, Nowalk, Yonas, Zimmerman and Ahmed (2012) 
indicated only 23% of providers reported consistent use of SOPs (Level I, Grade A).  The 
researchers aimed to identify factors either promoting or impeding the use of SOPs.  Reliability 
was strengthened through use of a survey that is national in scope and maintains a high provider 
response rate, while the questionnaire was rooted in concepts from various theoretical models.  
Investigators determined that consistent SOP use for influenza and pneumonia vaccination was 
significantly impacted by provider awareness of ACIP recommendations and/or Medicare 
regulations as those reporting consistent use of SOPs were typically more aware of said 
regulations and recommendations.  The same team conducted an additional study among 1,640 
providers and findings were similar, identifying the two variables mostly highly associated with 
a provider’s likelihood of using SOPs as awareness of recommendations to use them and 
agreement with their efficacy (Zimmerman, Albert, Nowalk, Yonas & Ahmed, 2011).  Both of 
these studies concluded providers who used them found they are beneficial; however, they also 
bring to light a need for greater awareness and methods to increase use of SOPs in primary care. 
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 Comparative findings were elicited by researchers Zimmerman et al. (2011) who 
conducted a quasi-experimental study among a stratified random sample of 1,640 providers 
within the U.S. (Level II, Grade B).  Consistent SOP use was reported slightly higher than the 
previous study at 42.4%.  The percentage of providers aware of ACIP/Medicare 
recommendations and regulations was 35.8% in the group not currently using SOPs, compared to 
70.9% in the group that was aware.  These findings further justify that awareness is critical to 
ensure successful implementation of an SOP and increase rates of vaccination; to be considered 
however, the method of data collection via survey is limited to self-report.  Regardless, methods 
that will increase use of SOPs are implicated for future research. 
Barriers to Immunization.  A multitude of barriers related to vaccine delivery exist 
within society as perceived by both patients and providers.  Much of the current literature aims to 
identify these barriers and address potential methods of alleviating them in attempts to raise 
vaccination rates.  A common theme across the literature is missed vaccine opportunities and the 
contribution it has to low vaccination rates.  In one retrospective study of 1,072 female girls 
between the ages of 18-24, it was found that 33.7% of the girls who did not receive their second 
vaccine in the series had at least one identifiable missed opportunity (Richards, Peters & 
Sheeder, 2014).  Similarly, Nowalk et al. (2005) conducted a cross-sectional analysis of 4,000 
patients in multiple primary care practices over a span of four years, yielding results with high 
sensitivity and generalizability.  The researchers identified an average of 10.7 +/- 7.3 missed 
opportunities for vaccination of adults 65 and older against pneumococcal pneumonia during the 
period of one year.   
Specific to provider and patient reported barriers, a survey conducted amongst 238 
OB/GYN U.S. medical residents reported barriers to immunization, which included uncertainty 
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over vaccine recommendations, safety and efficacy and a lack of time to properly inform patients 
of the risk and benefits to vaccination (Fay, Hoppe, Schulkin & Eckert, 2014).  It should be noted 
that these results are limited to providers of a medical specialty and may not be applicable to all 
providers.  Rehm et al. (2012) summarized similar findings elicited from a multidisciplinary task 
force meeting on ways to increase pneumococcal vaccination rates among older adults.  Barriers 
to vaccination included lack of awareness of the vaccine or disease, health care system delivery 
challenges and competing priorities that restricted the time available for vaccine discussion.  
Researchers Suryadevara et al. (2013) identified similarly expressed barriers in their study and 
attempted to eliminate them and improve rates of vaccination.  They partnered with the Salvation 
Army to educate families on childhood immunizations and by doing so, rates of vaccination 
increased from 28% to 45%.  Although further study specific to barriers again pneumococcal 
pneumonia vaccination in the older adult population is warranted, each of these articles 
successfully highlighted the significance of missed opportunities on vaccination rates.   
Summary of Evidence  
As research has demonstrated, disparities in pneumonia vaccination rates exist among the 
older adult population.  Despite the known efficacy and availability of vaccines, millions remain 
unvaccinated (ALA, 2010).  Barriers to full immunization do exist, but sufficient evidence 
proves they are surmountable.  Development and implementation of this program will address 
ways in which health care providers can begin rectifying the issue, starting with the simple task 
of increasing their awareness to existing recommendations and patient awareness to vaccine 
benefits; successful intervention will aid in minimizing this disparity by expanding provider’s 
abilities to offer patient services aligned with nationally established goals for prevention and 
control against vaccine preventable disease.  Vaccinations help to eliminate health disparities 
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while simultaneously advancing health equity among the population.  Utilizing detailed 
screening and not relying solely on the providers will help reduce the number of missed 
opportunities within this vulnerable population, and implementation of SOPs will positively 
affect vaccination rates. 
Theoretical Framework 
Lewin’s Change Theory 
In order to successfully motivate a collaborative team and advance toward achieving an 
optimal goal, one must be familiar with the concept of change and its theoretical underpinnings 
(Zaccagnini & White, 2014).  Developed by ‘the father of social psychology’, Kurt Lewin, the 
Change Theory of Nursing recognizes change as a constantly evolving factor of life, driven by a 
dynamic balance of forces working in opposing directions (Lewin, 1951; Lewin, 1975; 
Zaccagnini & White, 2014).  The social scientist believed driving forces facilitated change by 
pushing individuals in the desired direction, while restraining forces pushed individuals in 
opposite directions, consequently preventing it (Kritsonis, 2005).  Lewin’s theory is based on the 
belief that change process must go through three stages: unfreezing, moving, and refreezing 
(Lewin, 1951; Lewin, 1975; Zaccagnini & White, 2014).  
The first stage is unfreezing.  This step in the process identifies needs of an individual or 
group, while simultaneously preparing those involved to move forward from the existing 
situation, or status quo, to an improved level of practice.  The unfreezing phase helps to identify 
a potential method that will allow people to let go of counterproductive processes and is 
necessary to overcome strains of individual resistance and group conformity.  Kritsonis (2005) 
recognizes three ways unfreezing can be achieved: a) increase the driving forces which will aid 
in redirecting behavior away from the existing situation or status quo; b) eliminate restraining 
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forces responsible for hindering movement from the existing equilibrium; c) formulating a 
combination of the two previous methods.   
Once those involved are motivated to change, the second stage in the process can take 
place: moving.  The movement phase zeroes in on what exactly needs to be changed.  It 
involves addition of driving forces as a means of motivating and empowering individuals/the 
group to adopt a new and improved prospective; additionally, this phase attempts to minimize 
opposing forces that pose potential barriers to achieving the desired change (Lewin, 1951; 
Lewin, 1975; Zaccagnini & White, 2014).  The focus here is to move the target system to a 
new level of equilibrium with the assistance of competent leader (Kritsonis, 2005). 
The final stage, freezing, involves making the change permanent and cannot successfully 
occur until the change has been implemented (Lewin, 1951; Lewin, 1975; Zaccagnini & White, 
2014).  The purpose of this stage is to stabilize the new equilibrium by maintaining a balance 
between driving and restraining forces, and if this is done poorly, or not at all, the risk for 
reverting back to old behaviors is high (Kritsonis, 2005).  To ensure completion of this stage, 
leaders must consistently reinforce the new level of practice and promote continued use by 
members. 
Theory Application in Implementation 
A comprehensive breakdown of the theory’s major concepts and their applicability to the 
capstone project are reviewed below.  Driving forces were identified as supporting evidence-
based research, improved patient outcomes and decreased hospitalizations, decreased healthcare 
costs, and improved patient/staff safety.  Restraining forces included lack of perceived benefit, 
fear of adverse effects and lack of perceived severity of illness and provider’s lack of awareness 
to how little patients knew of this disease and available vaccines. 
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Unfreezing phase.  Achieving this step required an increase in driving forces and 
decrease in restraining forces.  This was accomplished by providing more educational materials 
on pneumococcal pneumonia and allowing patients the opportunity to ask questions and voice 
concerns during office visits.  Engaging patients instilled a sense of empowerment, helping them 
to overcome their resistance to change and gain a greater understanding of how important the 
need for change was (Sutherland, 2013).  Additionally, this time was used to discuss existing 
statistics with staff and providers, making them more aware of the need for increased education.  
Moving phase.  The moving phase included implementation of the intervention.  During 
this time, posters were placed in the waiting room; flyers were placed in each exam room and 
handed out to patients at both check-in and check-out, in addition to provision of VIS forms.  
Patients were encouraged to read the available material and ask questions during their visit in 
order to increase their knowledge of pneumococcal pneumonia and recognize the benefits of 
vaccination.   
Freezing phase.  Bozak (2003) identifies the need for the theory’s final stage to include 
stability and evaluation, which the DNP student achieved through the provision of ongoing 
support of all stakeholders during implementation of the intervention.  Adequate follow-up with 
patients and providers/staff offered a chance for feedback and ensured the new equilibrium was 
maintained.   
Project Design and Methods 
The project design looked at benchmark change in cumulative vaccination rates through 
use of an educational intervention aimed at both patients and the clinic.  Pre and post 
intervention data was analyzed to assess the impact of the project.  Project data was analyzed 
using mixed qualitative and quantitative methods.  The project intervention ran from November 
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2015 through February 2016.  Data regarding immunization rates for pneumococcal disease in 
the target population adults age 65 years and older was gathered and analyzed pre and post-
implementation, quantifying the number of eligible patients that received vaccination at each 
time interval and comparing results; this was completed with the assistance of the Information 
Technology department.  
Planning Model: CHIP 
The Community Health Improvement Process (CHIP) provides a systematic approach for 
how communities can identify and manage prevalent health issues in specified populations 
(IOM, 1997; Layde et al., 2012).  The model is separated into two cycles to further delineate key 
elements (Appendix C).  The first cycle, identification and prioritization, aided the DNP student 
in conducting the needs assessment and determining which health issue needed to be addressed; 
it is comprised of 3 core elements: 
• Form a community health coalition 
• Prepare and analyze community health profiles 
• Identify critical health issues 
Completion of the first cycle indicated a need for improving pneumonia vaccination rates.  
Subsequently, the student was able to initiate the second cycle of analysis and implementation, 
addressing seven additional elements: 
• Analyze health issue 
• Inventory resources 
• Develop health improvement strategy 
• Identify accountability 
• Develop indicator set 
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• Implement strategy 
• Monitor process and outcomes 
The CHIP model provided a framework for guiding the implementation of the capstone project 
and the assessment of outcomes for the future. 
Needs Assessment 
Community of Interest.  The chosen site for implementation was a group medical 
practice established in Central Massachusetts with 14 sites providing primary care and satellite 
sites providing specialty services.  Project implementation occurred at only one of the primary 
care locations.  The selected practice had a panel of approximately 12,000 patients, ranging from 
young adults to elderly, and nine providers: six MDs and four APRNs.  The providers saw on 
average anywhere between 80 and 130 patients a day for a combination of well and sick visits.  
Demographics within the practice were consistent with the surrounding town of Westborough, 
representing a dominantly middle to upper class Caucasian and Indian population.  The target 
population for project implementation included adults 65 years of age and older eligible for 
pneumococcal vaccination within the primary care setting; patients were excluded if they were 
new to the practice within the previous three months. 
Utilizing the feedback of multiple providers within the department through verbal 
discussion, it was determined that an intervention focusing on increasing vaccination rates was 
desired.  Most providers felt that the numbers of patients receiving the currently recommended 
vaccinations were lacking and wanted to see these numbers increase; although, there were a 
select few that did not feel their numbers were far off from national baselines.  Many patients felt 
improved efforts needed to be made by healthcare offices to remind patients when they are due 
for vaccines.  Interviewed individuals felt that if they forgot to ask about a vaccine they may 
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have seen on TV (i.e. the new CDC recommendations for PCV13) it may not have necessarily 
been recommended during the visit.  Statistical data was gathered to accurately demonstrate 
vaccination rates within this department.  Additionally, further investigation was undergone to 
highlight missed opportunities for vaccinating patients and identifying existing barriers (i.e. 
during a regular office visit vs. physical).  This information assisted the DNP student in 
identifying gaps or deficits comparatively speaking. 
Organizational Analysis 
Identifying the Key Stakeholder.  The key stakeholder for this project was a Master’s 
prepared FNP who works closely with her supervising physician, a family medicine doctor with 
nearly 40 years of experience in primary care.  On average she sees 15-20 patients a day, 
primarily 18 years and older, for both well and sick visits.  Although she does not have a panel of 
her own, she is well known to patients throughout the office and they often seek her care 
directly.   
Resources, Facilitators and Barriers.  Resources necessary to complete the capstone 
project included: time, location, materials and email communication.  Time was managed 
throughout the entire process to account for development, implementation and analysis of the 
quality improvement project.  A specific location was necessary to implement the project and 
approval to utilize this site was necessary to obtain.  Email was necessary to stay in constant 
contact with project stakeholders, particularly the IT department.  Materials included the supplies 
necessary for poster construction, paper and printer for flyer production and Vaccine Information 
Sheets, all of which helped facilitate information to patients.  Poster supplies were obtained on 
the DNP student’s budget, while the rest of the material was made available by the project site.  
Each of these interventional tools was beneficial in facilitating communication about 
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pneumococcal pneumonia between patients and providers. 
Vaccine Information Sheets (VIS) developed by the CDC were already being provided to 
patients in adherence to national regulations.  The CDC ensures these informational sheets are 
up-to-date; the PCV-13 VIS was most recently updated in November of 2015 and PPSV-23 in 
April of 2015.  Each of these is available in multiple patient languages and written in layman’s 
terms for patients to comprehend.  They explain to patients, parents or legal representatives of 
the individual being vaccinated, what the risks and benefits are to vaccination and address many 
of the commonly asks questions associated with the vaccination.   
Existing standard workflow processes within the office facilitated the project.  Trained 
nurses were available to administer vaccines or answer patient’s questions.  A designated nursing 
room allowed a space for patients to receive vaccines without having to wait and delay rooming 
of other patients, which was a perceived barrier expressed amongst office staff.  The office 
maintained stock of all necessary materials to facilitate vaccine administration, including PCV-13 
and PPSV-23 vaccines, needles, gauze and band aids.  Additionally, a crash cart with all items 
necessary for an emergency was readily available and appropriate staff was knowledgeable of its 
contents.  VIS forms were already present in all exam rooms and the nursing room; open 
communication between DNP student and staff ensured that these were consistently offered to 
patients.   
Potential barriers to project implementation were identified as provider/staff reluctance, 
lack of knowledge of vaccination coverage and an assumption of patient’s lack of perceived need 
and severity of illness.  Some providers were reluctant to rescind responsibilities of identifying 
eligible patients, while some expressed concern over it being the nurse’s sole responsibility to 
decide whether or not vaccination was appropriate.  Staff and providers identified their lack of 
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knowledge of vaccination coverage was a barrier to facilitating adequate monitoring of vulnerable 
patients.  Data gathered for pre-implementation analysis was provided to staff and providers to 
accurately depict vaccination rates within the department and demonstrate a need for 
improvement.   
It was determined that due to Internal Medicine and Pediatric departments combining for 
their annual flu clinic implementation during the clinic was too large of an undertaking.  The 
additional requirements on staff mentally, physically and financially were deemed too 
overwhelming.  It was determined among student and key stakeholder that the SOP would be 
best implemented as a part of the standard daily workflow.  By October, significant barriers to 
implementation became evident.  The company was undergoing a major layoff, management was 
reconstructing itself and employees at all levels were under great amounts of stress.  By 
November, the clinical nurse lead, and another key stakeholder for the project, resigned.  This 
was detrimental to project implementation as this nurse leader had been in support of the project 
and was helping facilitate nursing’s adaptation.  The DNP student met with the key stakeholder 
and practice manager in December to discuss plausible solutions.  
Project Implementation 
Ethics and Human Subjects Protection 
The chosen methods of design and evaluation were submitted to the UMass Amherst 
Institutional Review Board and determined to be exempt given the proposed activities were not 
considered research under the human subject regulations (Appendix D).  To avoid violation of 
HIPPA laws, the student at no time had access to any patient’s protected health information and 
their confidentiality was maintained.  To alleviate potential for representation of human subject 
research, the project was limited to the use of existing and/or prospectively collected de-
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identified patient data; IT gathered and supplied all necessary data for analyzing.   
Project Timeline 
A flow chart was developed to identify the program’s major processes and is available for 
review in Appendix E.  Constant reference to the original timeline and flowchart were made 
throughout the implementation process, allowing the student opportunities to acknowledge 
obstructing factors and ensure programmatic needs of the project were effectively being 
addressed.   
Pre-intervention.  The DNP student had previously met with both the project’s key 
stakeholder and office practice manager in late August 2015 and was granted permission to 
implement the project at their location.  Discussion at that time included the following key points 
that pertained to the proposed project’s design and evaluation methods: 
• Outcome goal: Determine if the intervention demonstrates a relationship between the 
health intervention program and the health outcome of the population (increased 
pneumonia vaccination rates among adults age 65 and older). 
• Project design: Quasi-experimental, pre and post-intervention. 
• Methods of evaluation: 
i. Quantitative data analysis/interpretation: 1) Pre and post intervention 
evaluation of the statistics pertaining to vaccination rates among patients 65 
and older within the practice.  
ii. Qualitative: Provision and review of patient and provider responses to an 
open-ended survey regarding the proposed intervention. 
 Communication with the IT department via email and phone occurred and data on 
current pneumococcal immunization rates for patients within the target audience was made 
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available to the student.  All data were given de-identified patient codes so as not to compromise 
patient confidentiality.   
By the end of October 2015 the project’s tactile materials were constructed to promote 
project awareness.  Flyers on pneumococcal pneumonia and vaccine promotion in patients 65 
and older were designed, printed and offered to patients during both check-in and check-out; 
they were also hung in patient exam rooms (Appendix F).  A poster board presentation with 
similar information was created and placed in the office waiting room for patients to view.  The 
office previously had vaccine information sheets available for both PCV-13 and PPSV-23 in the 
nursing treatment room.  The DNP student collaborated with staff and was able to have materials 
placed in all patient exam rooms by the end of October 2015.  By mid-October a PowerPoint 
presentation on pneumococcal pneumonia was developed and a copy of the pneumococcal 
pneumonia vaccine eligibility screening tool developed by the Immunization Action Coalition 
(2015) was printed and copied for providers and staff to review at the first educational session 
(Appendix G).  In addition, a survey was constructed to gain feedback from attendees at the 
educational session (Appendix H).  The survey included questions specific to the content of the 
DNP student’s presentation and three open-ended questions pertaining to the proposed capstone 
as a whole.  
During the early phases of implementation the company underwent a large layoff and 
scheduling conflicts occurred frequently due to structural changes and a need to address pressing 
issues within the company.  As a result, the DNP student was not able to present the project as 
anticipated.  Rather, multiple conversations were had between student and individual staff that 
would be affected by the project, including nurses, providers, medical assistants and secretaries.  
Despite ample support from key stakeholders and an overall desire within the office to improve 
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pneumococcal vaccination rates, mostly everyone were significantly less receptive to the idea 
that this would require a change in the workflow process.   
At the onset of the project the DNP student had engaged in multiple conversations with 
the clinical nurse supervisor who was in strong support of carrying out a standing orders 
program; however, by the end of October she had resigned and remaining staff nurses adamantly 
refused to adopt the proposed project.  Concerns were raised regarding recent layoffs and budget 
cuts placing too significant of a strain on their already understaffed team and they did not want to 
assume the responsibilities that came with a standing orders program.  Validation of their 
concerns was provided and it was acknowledged that a change in project focus was necessary.  
In the best interest of all participants involved in the project, it was decided that the DNP student 
would remove the existing intervention of a standing orders program and place emphasis on the 
educational component of the project.  By increasing the presence of informational material on 
pneumococcal pneumonia and available vaccinations, the hope was that immunization rates 
would raise.   
During Intervention.  During this interval the DNP student maintained supervision and 
offered support to patients and staff as necessary.  Periodic inspection of the project site was 
conducted by the student to ensure that posters were visible to patients, VIS forms were 
consistently being offered and flyers were being offered to patients appropriately.  Service 
utilization outputs were tracked, such as the number of materials developed for the 
implementation of the project and overall work flow, and a running log of project activities was 
maintained.   
Post-intervention.  Interpersonal information system outputs were requested and 
included all reports generated by IT.  The final report was generated and supplied to the student 
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via email.  Inputs and outputs to the service utilization plan were reviewed and quantified during 
this phase as necessary.  This included tracking of program coverage through collection of de-
identified patient data via IT to determine if the target audience had been reached successfully.  
Results were analyzed to determine the effectiveness and future applicability of the quality 
improvement project.  During the months of March and April 2016 the program was evaluated 
and discussions regarding program intervention delivery were had between the student and 
project facilitators.  Dissemination of project findings is projected to occur at the College of 
Nursing Scholarship Day, held on May 5, 2016 at the University of Massachusetts Amherst.  
Project Evaluation 
Data Analysis and Results 
 The project identified three major goals, each of which had associated objectives and 
specific measurable outcomes utilized to achieve the overarching goals of the project (Appendix 
I).  Analysis and interpretation of the data collected from IT was undergone to assess whether 
project goals were met and complete a program evaluation.   
 Goal I: Identify a multidisciplinary team within primary care to design and 
implement a program that meets both state and federal regulatory requirements and 
national vaccination goals.  Each of the objectives and measurable outcomes for this goal were 
specific to implementation of a standing orders program.  Given an SOP was not successfully 
implemented, objectives could not be met, and this goal by default was considered unattained.  
However, an alternative educational program was successfully implemented.   
 Goal II: Ensure all eligible adults age 65 and older in primary care are effectively 
motivated and informed of current pneumococcal vaccination recommendations and 
provided an opportunity for vaccination.  Again, failure to implement an SOP within the 
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office was a significant deterrent to satisfying all measurable outcomes of this goal.  However, 
despite the fact that original measurable outcomes were not met, the individual objectives were; 
therefore, this goal was arguably achieved.   
 Objective i: Establish baseline data for vaccination rates of patients aged 65 and older 
in the practice.  Baseline data was successfully obtained from IT by October 2015.  From a total 
clinic panel of 10,601 patients, it was established that 2,049 met the inclusion criteria for the 
project.  Of the eligible patients, 1,636 were shown to have previously received either one or 
both of the available pneumococcal pneumonia vaccines.  This objective was successfully met.  
 Objective ii:  Identify and eliminate missed vaccine opportunities.  Although this 
objective was not met with regards to the specified outcome measures, the DNP student did 
engage in individual in-depth interviews with providers and patients during the pre-intervention 
phase of the project to discuss barriers to vaccination and gain feedback on why they believed 
opportunities were missed.  Critical analysis of provider and patient responses was conducted.  
The two most common responses elicited from providers included frequent need to prioritize 
other concerns during office visits and the subsequent lack of adequate time to discuss the 
vaccine with their patients; however, providers expressed feeling methods to alleviate these 
barriers were scarce.  Similarly, patients felt dependent on their providers to raise the discussion 
of vaccines.  Lack of disease and vaccine awareness was also a major barrier identified by 
patients.   
 Objective iii: Increase patient awareness of pneumococcal disease and vaccine 
availability.  Nearly 100% of adult patients 65 and older had flyers readily available to them at 
check-in.  Informational flyers and an educational poster board were constructed by September 
2015 and made available for patient viewing by October 2015.  Additionally, patient and provider 
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responses to open-ended discussion yielded positive feedback.  The patients approached all 
expressed an appreciation for the increased presence of educational material and providers noted 
patients inquiring about the vaccine more frequently than previously.  The data was obtained 
sporadically and patient responses were not tracked; therefore, critical analysis of these results 
could not be completed.   
Goal III.  Reduce overall morbidity and mortality caused by pneumococcal disease 
among adults age 65 and older in primary care.  In order to adequately assess outcomes and 
evaluate whether the goal was met at project completion, the DNP student requested four 
specific data sets from the IT department to evaluate project impact; they included (a) the total 
number of patient’s on the clinic’s panel; (b) the total number of those patients 65 years and 
older not new to the practice within the last three months; (c) the total number of those patients 
65 years and older that have received either or both pneumococcal vaccines (PCV-13 and PPSV-
23); (d) the total number of those patients 65 years and older that have not received either 
vaccine.  IT conducted two separate reports to reflect data before and after intervention.  Table 1 
provides a comparative summary of results for each individual dataset before and after 
intervention and reveals the nearly 10% increase of cumulative vaccination rates among the 
target population after project implementation.   
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Table 1 
 
Data Comparing Pneumococcal Vaccination Rates in Adults 65 and Older Within Primary Care 
Before and After an Educational Intervention 
 
Dataset Pre-Intervention Post-Intervention 
Cumulative % a 
Pre Post 
Total # of patients in clinic 10,601         10,816  
Total # of patients ≥ 65 y/o b 2,049 1,994   
Vaccinated c 1,636 1,788 79.84% 89.67% 
Unvaccinated c 413 208  
Note. De-identified patient data collected from Reliant Medical Group, Active Patient Panel reports: November 
2015 and February 2016. 
a Cumulative percentages were calculated specifically utilizing pre and post-intervention samples separately.   
b Only patients that met inclusion criteria (adults age 65 and older, not new to the practice within the previous 3 
months and eligible to receive either vaccine without contraindication).  
c Total # calculated from patient sample that met inclusion criteria; these totals do not reflect the vaccination rates 
for the entire clinic’s panel; includes both PCV-13 and PPSV-23.  Individuals were counted only once as 
“vaccinated” regardless if they had received both or either vaccination multiple times.      
 
 Objective i:  Expand immunization services.  The measurable outcome for this objective 
aimed to have at least 75% of patient’s age 65 and older complete screening and receive a 
pneumococcal vaccine if determined eligible under the standing orders.  This outcome was 
realistically unattainable as an SOP was not implemented.   
 Objective ii:  Increase the annual immunization rates of adults age 65 and older who 
are vaccinated against pneumonia in primary care.  Primary data analysis was conducted using 
a chi-square test to determine whether increased patient education was directly related to 
increased vaccination rates.  Nominal values included 1) before vs. after project intervention, and 
2) how many patients were and were not vaccinated against pneumonia.  Utilizing the statistics 
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from Table 1, results indicated there was a statistically significant relationship between patient 
education and rates of vaccination χ2 (1) =73.74, p < .001.      
Descriptive analysis of the February 2016 active patient report yielded clinically 
significant results.  Approximately 1,788 (89.67%) patients age 65 and older in the primary care 
clinic had received either, or both, the PCV-13 and PPSV-23 vaccines, compared with 1,636 
(79.84%) in November 2015 (p=<.0001).  There was an overall increase of 9.83% in cumulative 
vaccination rates from project baseline.  Furthermore, the number of those unvaccinated was 
nearly cut in half after project implementation was complete (see Figure 1).   
Prior to the intervention, vaccination rates for the clinic among the target population were 
10.16% below Healthy People 2020 benchmark goal of 90%; the intervention minimized that 
gap to only 0.33% (see Figure 2).  The objective’s measurable outcomes called for a 20% 
improvement of cumulative vaccination rates and a match to the Healthy People 2020 goal of 
90%; therefore, the objective could only be observed as partially met.   
 
 
IMPROVING PNEUMONIA VACCINATION RATES 30 
 
 
Figure 1.  Patient pneumococcal vaccination status pre and post an educational 
intervention.  
 The bar graph compares pneumococcal vaccination rates among patients 65 years and 
older in a primary care setting.  Individuals were considered vaccinated if they had received 
either, or both, PCV-13 and PPSV-23 and unvaccinated if they had received neither.  The 
decrease in number of unvaccinated patients is consistent with the increase of total patients 
vaccinated.  Relative to the sample sizes before intervention (n=2,049) and after intervention 
(n=1,994), there was an overall cumulative vaccination rate increase of 9.83% among the total 
number of eligible patients vaccinated before and after project implementation (79.84% to 
89.67%, respectively).   
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Figure 2.  Pre and post intervention cumulative pneumococcal vaccination rates compared 
to the target goal of Healthy People 2020.   
This bar graph is a quantitative comparison of cumulative pneumococcal vaccination 
rates among the sample population before and after the educational intervention was 
implemented.  Patients included in the sample were adults 65 and older that were not new to the 
practice within the previous 3 months.  Results clearly demonstrate the 9.8% increase from 
baseline.  The results are displayed in relation to their achievement of Healthy People’s 2020 
benchmark goal of 90%, which is indicated by the red target line. 
Discussion 
Despite the fact that not all project objectives were met in terms of instituting standard 
orders the project did demonstrate the benefits of increased patient education on rates of 
vaccination.  Although the initial goal of implementing an SOP was not achieved, the fact that an 
alternative educational intervention was planned and implemented in accordance with both 
national and state guidelines cannot be discredited.  The U.S. Department of Health and Human 
Services (HHS) has established numerous initiatives and programs designed with the same 
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overarching goal in mind: strengthening adult vaccination.  This project aligned specifically with 
objectives and indicators of Healthy People 2020 and the Agency for Healthcare Research and 
Quality.  The project also built on existing initiatives at the state level as specified by the 
Massachusetts Department of Public Health (MDPH) (Executive Office of Health and Human 
Services, 2015).  As is the case with many of state projects, development of this capstone project 
followed recommendations of the CDC, including implementation of measurable increases and 
reduction of disparities in adult immunization rates (CDC, 2015).  Results of the project support 
previous studies that determined cumulative vaccination rates increased with the use of an 
educational intervention (Kemp, 2008; Yu, 2015).  These successes implicate both immediate 
and long-term achievement of a major project goal: Reduce overall morbidity and mortality 
caused by pneumococcal disease in the target population.   
The Healthy People 2020 target goal of 90% vaccination in this population lay right 
outside of reach and suggests that sustained efforts to improve cumulative vaccination rates 
through patient education are necessary.  However, it is of interest to note that 41 patients were 
excluded from the data analysis post-intervention as they were new to the practice within the 
previous three months.  Of these, 31 were vaccinated with either, or both, PCV-13 and PPSV-23.  
If data were to be collected on pneumococcal vaccination rates without consideration to this 
exclusion criteria, the true total number of vaccinated patients 65 and older within the clinic 
would be 1,819 (1,788 + 31); therefore raising the clinic’s cumulative vaccination rate to 91.22% 
and exceeding the Healthy People 2020 benchmark goal of 90%.   
The project goal to expand immunization services could understandably not be met, 
strictly because achievement of the measurable outcome required implementation of an SOP.  
However, by preventing missed vaccination opportunities in the future, eliminating barriers to 
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immunization and increasing overall patient awareness on pneumococcal pneumonia, the 
project’s outcomes certainly aid in the expansion and improvement of vaccination services 
within the primary care clinic.  The project identified patient and provider barriers that were 
largely consistent with those identified in previous qualitative studies (Albert et al., 2012; Appel, 
2011; Burns & Zimmerman, 2006; Hurley et al., 2014; Rehm, 2012; Richards et al., 2014).  
Furthermore, the project’s findings also support the use of patient education as a quality tool for 
removing certain barriers (Suryadevara et al., 2013).  This reinforces the notion that improved 
efforts to identify barriers to immunization are necessary to improve pneumococcal vaccination 
rates among adults 65 and older in primary care (Rehm, 2012).  Further research on methods to 
eliminate common barriers to vaccination is necessary. 
Similar to previous research findings, providers felt that the  increased education resulted 
in more patients mentioning the vaccine during visits and patients reported feeling better informed 
of the disease and vaccines (Smith & Metzger, 2011; Suryadevara et al., 2013; Yu, 2015).  
Additionally, critical analysis of the responses clearly supported prior researcher’s claims that 
increased presence of educational material in primary care clinics subsequently increased the 
amount of patients inquiring about the vaccines (Nowalk et al., 2014).  It should be noted that 
open-ended discussion was conducted among random patients and providers and may have 
limited generalizability; furthermore, future studies of a similar nature would benefit from 
tracking the number and responses of individuals interviewed to analyze data more accurately and 
avoid potential threats to project validity.  Regardless, the project’s findings underscore the need 
to increase patient education on pneumococcal pneumonia and available vaccinations.   
Results of this DNP project also add to existing literature suggesting that Lewin’s Theory 
of Change can be utilized as framework to motivate acceptance of change among both patients 
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and providers.  Lewin’s theory argues that in order for change to be successful, three phases must 
occur: unfreezing, moving and freezing (Lewin, 1951; Lewin, 1975; Zaccagnini & White, 2014).  
The provider’s acknowledgment of driving and restraining forces to immunization throughout the 
unfreezing and moving phases reminded them of the integral role they play in ensuring patients 
are well informed of vaccine recommendations.  Of equal importance, the framework also guided 
patients in recognizing and accepting responsibility of their role in maintaining their health; thus 
improving the level of practice among both entities.  The clinic has proven able to adopt Lewin’s 
theory and could benefit from continued efforts in identifying and eliminating gaps in healthcare 
quality by utilizing the framework.   
Study Limitations.  This study was subjected to several limitations.  Most significantly, 
the implementation of a standing orders program was unsuccessful due to changes in the 
workplace.  The initial implementation of an SOP seemed feasible for both student and project 
key stakeholders but structural barriers within the company were too significant to overcome.  
Additionally, the loss of support from the nurse lead resulted in significant resistance from the 
nurses, whose participation was crucial to project success.  Future studies of a similar nature 
would benefit from greater involvement of multidisciplinary stakeholders to act as liaisons 
between student and staff.   
 Limitations also existed within the study’s methods and designs.  First, the pre-post 
intervention design was most feasible given timing and logistical constraints; however, without 
follow-up it lacks the ability to evaluate long-term effectiveness of the intervention.  Second, 
participants were recruited from a convenience sample, lacking randomization or inclusion of a 
control group.  Inability to control variables limits the ability to make casual inferences and 
leaves question surrounding whether there may have been alternative explanations for the 
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project’s outcomes.  Third, being that the project was constrained to one primary care location 
findings may be limited in generalizability.  However, comparative results to previous studies 
with similar patient population’s leads the DNP student to speculate it was a fairly accurate 
depiction of the population, thus strengthening the project’s external validity.  Future research 
should consider the effect of these limitations on the study’s findings and address them 
accordingly.  
 Conclusion 
Primary care providers uphold a pivotal role in preventive health maintenance, including 
immunizations.  This DNP project aimed to assess the feasibility of implementing a theory-
driven, evidence-based educational intervention to increase rates of pneumococcal pneumonia in 
adults 65 and older within the primary care setting.  Results indicated that by increasing the 
presence of educational material and introducing greater opportunities for patients to seek 
information, the DNP student was able to increase cumulative rates of pneumococcal vaccination 
(PCV-13 and PPSV-23) in the at risk population by nearly 10%.  Furthermore, the project 
elicited findings supportive of previous research, indicating that educational interventions aimed 
at both patients and providers, are a plausible means of dismantling barriers and increasing 
cumulative rates of vaccination in high-risk patient populations.   
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Appendix A 
 
Use of 13-Valent Pneumococcal Conjugate Vaccine and 
23-Valent Pneumococcal Polysaccharide Vaccine Among Adults 
Aged ≥65 Years: Recommendations of the Advisory Committee on 
Immunization Practices (ACIP) 
Sara Tomczyk, MSc1,2, Nancy M. Bennett, MD3,4, Charles Stoecker, PhD5, Ryan Gierke, MPH2, Matthew R. Moore, MD2, 
Cynthia G. Whitney, MD2, Stephen Hadler, MD2, Tamara Pilishvili, MPH2 (Author affiliations at end of  text) 
 
 
On August 13, 2014, the Advisory Committee on Immunization 
Practices (ACIP) recommended routine use of 13-valent pneu- 
mococcal conjugate vaccine (PCV13 [Prevnar 13, Wyeth 
Pharmaceuticals, Inc., a subsidiary of Pfizer Inc.]) among adults 
aged ≥65 years. PCV13 should be administered in series with 
the 23-valent pneumococcal polysaccharide vaccine (PPSV23 
[Pneumovax23, Merck & Co., Inc.]), the vaccine currently recom- 
mended for adults aged ≥65 years. PCV13 was approved by the 
Food and Drug Administration (FDA) in late 2011 for use among 
adults aged ≥50 years. In June 2014, the results of a randomized 
placebo-controlled trial evaluating efficacy of PCV13 for pre- 
venting community-acquired pneumonia among approximately 
 
85,000 adults aged≥65 years with no prior pneumococcal vaccina- 
tion history (CAPiTA trial) became available and were presented 
to ACIP (1). The evidence supporting PCV13 vaccination of 
adults was evaluated using the Grading of Recommendations, 
Assessment,Development,andEvaluation(GRADE)framework 
and determined to be type 2 (moderate level of evidence); the rec- 
ommendation was categorized as a Category A recommendation 
(2). This report outlines the new recommendations for PCV13 
use, provides guidance for use of PCV13 and PPSV23 among 
adults aged ≥65 years, and summarizes the evidence considered 
by ACIP to make this recommendation. 
 
Epidemiology of Pneumococcal Disease Among 
Adults Aged ≥65 Years 
Streptococcus pneumoniae (pneumococcus) remains a lead- 
ing infectious cause of serious illness, including bacteremia, 
meningitis, and pneumonia, among older adults in the United 
States. Use of a 7-valent pneumococcal conjugate vaccine 
(PCV7) since 2000 and PCV13 since 2010 among children 
in the United States has reduced pneumococcal infections 
directly and indirectly among children, and indirectly among 
adults. By 2013, the incidence of invasive pneumococcal 
disease (IPD) caused by serotypes unique to PCV13 among 
adults aged ≥65 years had declined by approximately 50% 
compared with 2010, when PCV13 replaced PCV7 in the 
pediatric immunization schedule (3). However, in 2013 an 
estimated 13,500 cases of IPD occurred among adults aged 
≥65 years (3). Approximately, 20%–25% of IPD cases and 
10% of community-acquired pneumonia cases in adults aged 
≥65 years are caused by PCV13 serotypes and are potentially 
preventable with the use of PCV13 in this population (3,4). 
 
PCV13 Vaccine in Adults 
On December 30, 2011, PCV13 was approved for use among 
adults aged ≥50 years to prevent pneumonia and invasive disease 
caused by S. pneumoniae serotypes contained in the vaccine. The 
new use for Prevnar 13 was approved under FDA’s accelerated 
approval pathway, which allows for earlier approval of prod- 
ucts that provide meaningful therapeutic benefit over  existing 
Recommendations for routine use of vaccines in 
children, adolescents, and adults are developed by 
the Advisory Committee on Immunization Practices 
(ACIP). ACIP is chartered as a federal advisory com- 
mittee to provide expert external advice and guidance 
to the Director of the Centers for Disease Control 
and Prevention (CDC) on use of vaccines and related 
agents for the control of vaccine-preventable diseases in 
the civilian population of the United States. Rec- 
ommendations for routine use of vaccines in children 
and adolescents are harmonized to the greatest extent 
possible with recommendations made by the American 
Academy of Pediatrics (AAP), the American Academy 
of Family Physicians (AAFP), and the American Col- 
lege of Obstetrics and Gynecology (ACOG). Recom- 
mendations for routine use of vaccines in adults are 
harmonized with recommendations of AAFP, ACOG, 
and the American College of Physicians (ACP). 
ACIP recommendations adopted by the CDC Direc- 
tor become agency guidelines on the date published in 
the Morbidity and Mortality Weekly Report 
(MMWR). Additional information regarding ACIP 
is available at http://www.cdc.gov/vaccines/acip. 
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treatments for serious and life-threatening illnesses (5). FDA 
defined “meaningful therapeutic benefit over existing treatments” 
as protection of adults aged ≥50 years from nonbacteremic 
pneumococcal pneumonia or nonbacteremic pneumococcal 
pneumonia combined with protection from IPD (7). On June 20, 
2012,ACIPrecommendedroutineuseofPCV13foradultsaged 
≥19 years with immunocompromising conditions, functional or 
anatomicasplenia,cerebrospinalfluidleak,or cochlearimplants 
(6).The ACIPdecisionto recommendPCV13 use amongadults 
aged≥65yearswasdeferreduntildatabecameavailableon1)the 
impactofPCV13useinchildrenondiseaseinadults(i.e.,indirect 
effects) and 2) the efficacyof PCV13 against noninvasive pneu- 
mococcalpneumoniaamongadults.In accordancewithacceler- 
ated approval requirements, a randomized placebo-controlled 
trial (CAPiTA trial) was conducted in the Netherlands among 
approximately85,000 adults aged ≥65 years during 2008–2013 
to verify and describe further the clinical benefit of PCV13 in 
the prevention of pneumococcal pneumonia (1). The results of 
theCAPiTAtrialdemonstrated45.6%(95%confidenceinterval 
[CI] = 21.8%–62.5%) efficacy of PCV13 against vaccine-type 
pneumococcalpneumonia,45.0%(CI=14.2%–65.3%)efficacy 
against vaccine-type nonbacteremic pneumococcal pneumonia, 
and 75.0% (CI = 41.4%–90.8%) efficacy against vaccine-type 
IPD among adults aged ≥65 years (1). 
Two randomized, multicenter, immunogenicity studies con- 
ducted in the United States and Europe among older adults 
showed that PCV13 induced an immune response as good 
as or better than that induced by PPSV23 (7,8). Functional 
antibody responses were measured 1 month after vaccination 
using an opsonophagocytic activity (OPA) assay. In adults aged 
60–64 years with no prior pneumococcal vaccination, PCV13 
elicited OPA geometric mean antibody titers (GMTs) to the 
12 serotypescommontoboth vaccinesthat were comparable 
with, or higher than, responses elicited by PPSV23 (7). In 
adults aged ≥70 years who previously had been immunized with 
asingledose of PPSV23 ≥5 yearsbeforeenrollment, PCV13 
elicited OPA responses that were comparable with those elicited 
by PPSV23 for two serotypes andhigherfor 10 serotypes(8). 
Immunogenicity studies evaluating responses to PCV7 
and PPSV23 administered in series showed a better immune 
response when PCV7 was administered first (9–12). An evalu- 
ation of immune response after a second pneumococcal vacci- 
nation administered 1 year after the initial study doses showed 
thatsubjectswhoreceivedPPSV23astheinitialstudydosehad 
lower OPA antibody responses after subsequent administration 
of PCV13 than those who had received PCV13 as the initial 
dosefollowedbyadoseof PPSV23, regardlessofthe level of 
the initial OPA response to PPSV23 (9). Studies evaluating 
the immune response after a sequence of PCV7 or PCV13 
 
 
followed by PPSV23 with intervals of 2, 6, and 12 months or 
3–4 yearsdemonstratedthatafterthe PPSV23dose,antibody 
levels were higher than the pre-PCV baseline, and a nonin- 
ferior response was observed when compared with post-PCV 
antibodylevels (9–12). None of the studies were designed to 
evaluate the optimal interval between vaccine doses. 
Safety of PCV13 was evaluated in approximately 6,000 
PPSV23-naïve and PPSV23-experienced adults aged ≥50 years 
(13). Overall incidence of serious adverse events reported within 
1 month of an initial study dose of PCV13 or PPSV23 did 
not differ between the two vaccines and ranged from 0.2% to 
1.7%. From1 to 6 months after an initial study dose, theoverall 
incidence of serious adverse events ranged from 1.2% to 5.8% 
among persons vaccinated with PCV13 and 2.4% to 5.5% 
among persons vaccinated with PPSV23. Rates of reported seri- 
ous adverse events in the treatment groups were similar among 
studies that enrolled PPSV23-naïve subjects and studies that 
enrolled PPSV23-experienced subjects. Common adverse reac- 
tions reported with PCV13 were pain, redness, and swelling at 
the injection site; limitation of movement of the arm in which 
the injection was given; fatigue; headache; chills; decreased appe- 
tite; generalized muscle pain; and joint pain. Similar reactions 
wereobservedin adultswhoreceivedPPSV23(13). 
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What is currently recommended? 
In 2010, the Advisory Committee on Immunization Practices 
(ACIP) approved revised recommendations that all persons 
should be vaccinated with 23-valent pneumococcal polysaccha- 
ride vaccine (PPSV23) at age 65 years. In 2012, ACIP made 
recommendations for use of 13-valent pneumococcal conjugate 
vaccine (PCV13) and PPSV23 for adults aged ≥19 years with 
immunocompromising conditions. 
Why are the recommendations being modified now? 
PCV13 was approved by the Food and Drug Administration in 
late 2011 for use among adults aged ≥50 years. In June 2014, 
the results of a randomized placebo-controlled trial showing 
efficacy of PCV13 against community-acquired pneumonia 
among approximately 85,000 adults aged ≥65 years became 
available and were presented to ACIP. The evidence supporting 
PCV13 vaccination of adults was evaluated using the Grading of 
Recommendations, Assessment, Development, and Evaluation 
(GRADE) framework and determined to be type 2 (moderate 
level of evidence); the recommendation was designated as a 
Category A recommendation. 
What are the new recommendations? 
Both PCV13 and PPSV23 should be routinely administered in 
series to all adults aged ≥65 years. The recommendations for 
routine PCV13 use among adults aged ≥65 years will be reevalu- 
ated in 2018 and revised as needed. ACIP recommendations for 
routine use of PCV13 in adults aged ≥19 years with immunocom- 
promising conditions, functional or anatomic asplenia, cerebro- 
spinal fluid leak, or cochlear implants remain unchanged. 
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Indirect effects from PCV13 use among children, if similar to 
those observed after PCV7 introduction, might further reduce 
the remaining burden of adult pneumococcal disease causedby 
PCV13-types. A preliminary analysis using a probabilistic model 
following a single cohort of persons aged 65 years demonstrated 
thataddinga dose of PCV13 to the currentPPSV23 recommenda- 
tions for adults aged ≥65 years, compared with current PPSV23 
recommendations, would lead to additional health benefits (14). 
This strategy would prevent an estimated 230 cases of IPD and 
approximately 12,000 cases of community-acquired pneumonia 
overthelifetimeofa singlecohortof personsaged65years,assum- 
ing current indirect effects from thechild immunization program 
and currentPPSV23vaccinationcoverageamongadultsaged ≥65 
years (approximately 60%). In a setting of fully realized indirect 
effects assuming the same vaccination coverage, the expected 
benefits of PCV13 use among this cohort will likely decline to 
an estimated 160 cases of IPD and 4,500 cases of community- 
acquired pneumonia averted among persons aged ≥65 years (14). 
CDC will assess the implementation and impact of the recom- 
mendation for PCV13 use among adults aged≥65 years, including 
coverage with PCV13 and PPSV23, and impact of PCV13 on 
vaccine-type IPD burden and community-acquired pneumonia. 
Monitoringdiseasetrendsamongadultswhodo   notreceivePCV13 
might help quantify indirect effects and the long-term utility of 
routine PCV13 use among adults. ACIP will be updated routinely 
on changes in the burden of IPD and community-acquired pneu- 
monia among adults during the next 3 years to determine the need 
for revisions to the adult PCV13 recommendations. 
 
PPSV23 inAdults 
A single dose of PPSV23 is recommended for routine use in 
the United States among adults aged ≥65 years (15). Effectiveness 
of PPSV23 in preventing IPD in adults has been demonstrated, 
but the data on the effectiveness of this vaccine in preventing 
noninvasive pneumococcal pneumonia among adults aged≥65 
years have been inconsistent. PPSV23 contains 12 serotypes in 
common with PCV13 and 11 additional serotypes. In 2013, 38% 
of IPD among adults aged ≥65 years was caused by serotypes 
unique to PPSV23 (3). Given the high proportion of IPD caused 
by serotypes unique to PPSV23, broader protection is expectedto 
be provided through use of both PCV13 and PPSV23 in series. 
ACIP considered multiple factors when determining the opti- 
mal interval between a dose of PCV13 and PPSV23, including 
immune response, safety, the risk window for protection against 
disease caused by serotypes unique to PPSV23, as well as timing 
for the next visit to the vaccination provider. 
 
ACIP Recommendations for PCV13 and PPSV23 Use 
Both PCV13 and PPSV23 should be administered routinely 
in series to all adults aged ≥65 years (Box). 
 
 
 
Pneumococcal vaccine-naïve persons. Adults aged ≥65 years 
who have not previously received pneumococcal vaccine or 
whose previous vaccination history is unknown should receive 
a dose of PCV13 first, followed by a dose of PPSV23. The 
dose of PPSV23 should be given 6–12 months after a dose of 
PCV13. If PPSV23 cannot be given during this time window, 
the dose of PPSV23 should be given during the next visit. The 
two vaccines should not be coadministered, and the minimum 
acceptable interval between PCV13 and PPSV23 is 8 weeks. 
Previous vaccination with PPSV23. Adults aged ≥65 years who 
have previously received ≥1 doses of PPSV23 also should receive a 
dose of PCV13 if they have not yet received it. A dose of PCV13 
should be given ≥1 year after receipt of the most recent PPSV23 dose. 
For those for whom an additional dose of PPSV23 is indicated, this 
subsequent PPSV23 dose should be given 6–12 months after PCV13 
and ≥5 years after the most recent dose of PPSV23 (15). 
Potential Time-Limited Utility of Routine PCV13 Use 
Among Adults≥65 Years.The recommendations for routine 
PCV13 use among adults aged ≥65 years will be reevaluated 
in 2018 and revised as needed. 
ACIP recommendations for routine use of PCV13 in adults 
aged ≥19 years with immunocompromising conditions, func- 
tional or anatomic asplenia, cerebrospinal fluid leak, or cochlear 
implants remain unchanged (6). 
 
Coadministration with Other Vaccines 
Concomitant administration of PCV13 and trivalent inacti- 
vated influenza vaccine (TIV) has been demonstrated to be immu- 
nogenic and safe. PCV13 can be coadministered with TIV in an 
adult immunization program. However, a randomized double- 
blind trial found slightly lower pneumococcal serotype–specific 
geometric mean concentrations and lower proportion achieving 
at least a fourfold rise in hemagglutination inhibition assay titer 
for one of three influenza subtypes (influenza A[H3N2]) with 
PCV13 plus TIV compared with PCV13 alone or TIV alone 
among adults aged ≥65 years (16). Currently, no data are available 
on coadministration with other vaccines (e.g., tetanus, diphtheria, 
and acellular pertussis vaccine or zoster vaccine) among adults. 
 
Precautions and Contraindications 
Before administering PCV13, vaccination providers should 
consult the package insert for precautions, warnings, and 
contraindications. Vaccination with PCV13 is contraindicated 
in persons known to have a severe allergic reaction (e.g., ana- 
phylaxis) to any component of PCV13 or PCV7 or to any 
diphtheria  toxoid–containing vaccine. 
Adverse events occurring after administration of any vaccine 
should bereportedtotheVaccineAdverseEventReportingSystem 
(VAERS). Reports can be submitted to VAERS online, by fax, 
 
 
824 MMWR /  September 19, 2014 / Vol. 63 /  No. 37 
IMPROVING PNEUMONIA VACCINATION RATES 45 
 
 
 
 
BOX. Sequential administration and recommended intervals for 
PCV13 and PPSV23 for adultsaged ≥65 years — Advisory Committee 
on Immunization Practices, United States 
 
 
or by mail. Additional information about VAERS is available by 
telephone (1-800-822-7967) or online (http://vaers.hhs.gov). 
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Announcement   
 
 
Now Available Online: Final 2013–14 Influenza Vaccination Coverage Estimates for Selected Local Areas, 
States, and the United States 
Final 2013–14 influenza season vaccination coverage esti- mates are now available online at FluVaxView (http://www.cdc. 
gov/flu/fluvaxview).The online information includes estimates of the cumulative percentage of persons vaccinated by the end of 
each month, from July 2013 through May 2014, for select local areas, each state, each U.S. Department of Health and Human 
Services region, and the United States overall. 
Analyses were conducted using National Immunization Survey influenza vaccination data for children aged 6 months–17 years and 
Behavioral Risk Factor Surveillance System data for adults aged ≥18 years. Estimates are provided by age group and race/ ethnicity. 
These estimates are presented in an interactive report (http://www.cdc.gov/flu/fluvaxview/interactive.htm) and complemented 
by an online summary report (http://www.cdc. gov/flu/fluvaxview/coverage-1314estimates.htm). 
 
QuickStats   
 
 
FROMTHENATIONAL CENTERFORHEALTHSTATISTICS 
 
Age-Adjusted Death Rates* for Heart Disease and Cancer,† by Sex 
— United States, 1980–2011 
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* Per 100,000 population. 
† As the underlying cause of death, heart disease is coded as 390–398, 402, and 404–429 for the 
period 1980–1998, and I00–I09, I11, I13, and I20–I51 for 1999–2011. As the underlying cause of death, 
cancer is coded as 140–208 for the period 1980–1998 and C00–C97 for 1999–2011, based on the 
International Classification of Diseases, Ninth and Tenth Revisions. 
 
 
During 1980–2011, age-adjusted death rates for heart disease in males and females decreased steadily. The rate 
decreased 59.5% for males and 56.8% for females. In contrast, the rate from cancer first increased 3.4% for males and 
5.3% for females during 1980–1990 and then decreased 27.2% for males and 18.0% for females by 2011. For females, the 
rates for cancer (147.4 per 100,000 population) surpassed the rates for heart disease (146.6) in 2009. The death rate for heart 
disease in males remained slightly higher (218.1) than the death rate for cancer (204.0) in 2011. 
Source: National Vital Statistics System. Mortality public use data files, 1980–2011.  Available at http://www.cdc.gov/nchs/data_access/ 
vitalstatsonline.htm. 
Reported by: Jiaquan Xu, MD, jax4@cdc.gov, 301-458-4086. 
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Appendix B 
 
Standing Orders for Administering Pneumococcal (PPSV23 and PCV13) Vaccine to  Adults 
 
 
Purpose: To reduce morbidity and mortality from pneumococcal disease by vaccinating all adults who meet the criteria established 
by the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices. 
Policy: Under these standing orders, eligible nurses and other healthcare professionals (e.g., pharmacists), where allowed by state law, 
may vaccinate adults who meet any of the criteria  below. 
Procedure 
1. Identify adults in need of vaccination with pneumococcal conjugate vaccine (PCV13) based on the following criteria: 
a. Age 65 years or older with no or unknown history of prior receipt of PCV13 
b. Age 19 through 64 years with no or unknown history of prior receipt of PCV13 and any of the followingconditions: 
i. candidate for or recipient of cochlear implant; cerebrospinal fluid leak 
ii. functional or anatomic asplenia (e.g., sickle cell disease, splenectomy) 
iii. immunocompromising condition (e.g., HIV infection, congenital immunodeficiency, hematologic and solid tumors) 
iv. immunosuppressive therapy (e.g., alkylating agents, antimetabolites, long-term systemic corticosteroids, radiation 
therapy) 
v. organ or bone marrow transplantation; chronic renal failure or nephrotic syndrome 
2. Identify adults in need of vaccination with pneumococcal polysaccharide vaccine (PPSV23) based on the following criteria: 
a. Age 65 years or older with no or unknown history of prior receipt of PPSV23 
b. Age 19 through 64 years with no or unknown history of prior receipt of PPSV23 and any of the following conditions: 
i. chronic cardiovascular disease (e.g., congestive heart failure, cardiomyopathies) 
ii. chronic pulmonary disease (e.g., chronic obstructive pulmonary disease, emphysema, asthma) 
iii. diabetes mellitus, alcoholism or chronic liver disease (cirrhosis), cigarette smoker 
iv. any of the conditions specified in categories 1.b. above 
3. Identify adults in need of an additional dose of PPSV23 if 5 or more years have elapsed since the previous dose of PPSV23 
and the patient meets one of the following criteria: 
a. Age 65 years or older and received prior PPSV vaccination before age 65 years 
b. Age 19 through 64 years and at highest risk for serious pneumococcal infection or likely to have a rapid decline in 
pneumococcal antibody levels (i.e., categories 1.b.ii.–1.b.v. above) 
4. Screen all patients for contraindications and precautions to pneumococcal vaccine: 
a. Contraindication: a history of a serious reaction (e.g., anaphylaxis) after a previous dose of pneumococcal vaccine (PPSV or 
PCV13) or to a vaccine component. For a information on vaccine components, refer to the manufacturer’s package insert 
(www.immunize.org/package- inserts) or go to www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/B/excipient- 
table-2.pdf. 
b. Precaution: moderate or severe acute illness with or without fever 
5. Provide all patients with a copy of the most current federal Vaccine Information Statement (VIS). While only the VIS for PCV13 
is required by federal law, it is prudent to also provide the VIS for PPSV23 to patients receiving PPSV23. For both vaccines, 
document in the patient’s medi- cal record or office log, the publication date of the VIS and the date it was given to the patient. 
Provide non-English speaking patients with a copy of the VIS in their native language, if available and preferred; these can be 
found at www.immunize.org/vis. 
6. Administer vaccine as follows: 
a. For adults identified in 1. above, administer 0.5 mL PCV13 intramuscularly (22–25g, 1–1½" needle) in the deltoid muscle. 
b. For adults identified in 2. and 3. above, administer 0.5 mL PPSV23 vaccine either intramuscularly (22–25g, 1–1½" needle) 
in the deltoid muscle or subcutaneously (23–25g, 5/ " needle) in the posterolateral fat of the upper arm. 
c. For adults in need of both PCV13 and PPSV23, administer PCV13 first, followed by PPSV23 in 6–12 months. (Note: for 
adults with im- munocompromising conditions or functional or anatomic asplenia, give PPSV23 8 weeks following 
PCV13.) If previously vaccinated with PPSV23, give PCV13 at least 12 months following PPSV23. Do not give PCV13 
and PPSV23 at the same visit. 
(Note: A 5/8" needle may be used for IM injection for patients who weigh less than 130 lbs [60kg] for injection in the deltoid 
muscle, only if the subcutaneous tissue is not bunched and the injection is made at a 90-degree angle.) 
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7. Document each patient’s vaccine administration information and follow up in the following places: 
a. Medical chart: Record the date the vaccine was administered, the manufacturer and lot number, the 
vaccination site and route, and the name and title of the person administering the vaccine. If vaccine was not 
given, record the reason(s) for non-receipt of the vaccine (e.g., medical contraindication, patient refusal). 
b. Personal immunization record card: Record the date of vaccination and the name/location of the administering 
clinic. 
8. Be prepared for management of a medical emergency related to the administration of vaccine by having a written 
emergency medical proto- col available, as well as equipment and medications. 
9. Report all adverse reactions to PPSV23 and PCV13 to the federal Vaccine Adverse Event Reporting System 
(VAERS) at www.vaers.hhs.gov or by calling (800) 822-7967. VAERS report forms are available at 
www.vaers.hhs.gov. 
This policy and procedure shall remain in effect for all patients of   the  until  
rescinded or until (date). (name of practice orclinic) 
Medical Director’s signature: Effective date:    
 
For standing orders for other vaccines, go to www.immunize.org/standing- 
orders Technical content reviewed by the Centers for 
Disease Control and 
Prevention 
Immunization Action Coalition Saint Paul, Minnesota • 651-647-9009 • www.immunize.org • 
www.vaccineinformation.org 
www.immunize.org/catg.d/p3075.pdf • 
Item #P3075 (10/14) 
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Appendix C 
Community Health Improve Process (CHIP) 
 
 
Adapted from “Improving Health in the Community: A Role for Performance Monitoring,” by J.S. 
Durch, L.A. Bailey, and M.A. Stoto, 1997, International Journal of Health Planning and 
Management,13(2), p. 191-192. Copyright 1997 by the National Academy Press. 
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Appendix E 
 
Flow Chart of Program Processes 
 
 
 
Educate Key Stakeholders  
 Provide project manager and site chief with cost/benefit analyses 
 Conduct educational/training session with staff/providers 
 PowerPoint presentation on pneumococcal pneumonia, benefits to vaccination and the benefits 
to the proposed project 
 Increase providers awareness of ACIP recommended standing orders for PPSV-23/PCV-13 
vaccines; offer copy  
 Post-educational session surveys, including open-ended questions, to assess opinions and 
willingness to participate  
 Address potential barriers and methods to eliminate them 
 Remain available to address questions/concerns of staff/providers  
Promote Project Awareness Among Patients 
 Provide patients with Vaccine Information Sheets   
 Hang and distribute flyers with pertinent information regarding pneumococcal pneumonia and 
the importance of vaccination  
 Encourage providers and staff to educate patients on pneumococcal pneumonia and 
vaccination during any available and appropriate opportunity 
Implement/Evaluate Intervention 
 Gather and analyze pre/post-intervention de-identified data on pneumococcal vaccination rates 
among target population  
Assess program effectiveness and future 
applicability; share findings with key 
stakeholders and student’s capstone 
committee 
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Appendix F 
 
What Is Pneumococcal Disease? 
 
 
Pneumococcal disease is one of 
the leading causes of death 
throughout the world. It is an 
easily  transmitted, 
significantly  infectiousillness 
cause by a commonbacteria 
pneumococcus, and resultsin 
massive expense, 
complications  (i.e. pneumonia, 
meningitis or sepsis) and 
 
death every year in the U.S. 
(American Lung Association 
[ALA], 2010). Nearly one 
million people willdevelop 
pneumococcal  pneumoniain 
the U.S. in the next year and 5 
to 7 perfect of them will die; 
the death rate is even higher 
in adults 65 years of age and 
older. 
Why Vaccinate? 
• • • 
Getting vaccinated is the most 
effective and safest way to protect 
yourself and your loved ones. 
 
Many studies have demonstrated 
pneumococcal vaccination to 
effective protect against invasive 
and noninvasive pneumococcal 
disease. 
 
 
 
Pneumococcal disease claims the lives of one in 
every four to five people over the age of 65 that 
contracts it. 
 
 
Did You Know? 
Adults 65 and older are at a  higher risk. 
Vaccines aid in protecting your 
body against various strains of 
bacteria. 
 
There are two currently 
recommended vaccines for older 
adults: 
 
• Pneumococcal Polysaccharide 
(PPSV23) 
As humans age our immune 
defenses become weaker, 
making us more susceptible to 
illnesses such as pneumonia. 
Patients suffering from 
chronic diseases are further 
limited in their ability to fight 
infection and suffer a greater 
risk for potential 
complications. According to 
the CDC (2011), 80% of older 
adults are diagnosed with a 
chronic illness and 50% with 
two or more. 
 
 
FAST FACT: 
Patients 65 and older have 
the highest expenditures of 
pneumonia among all age 
groups in the U.S. 
• Pneumococcal Conjugate 
(PCV13) 
 
Some strains of  pneumococcal 
are resistant to antibiotics, 
making infections difficult to 
treat. 
Prevention through 
vaccination
Pneumococcal Disease: 
Are You and Your Loved Ones Protected ? 
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Appendix G 
 
 
Screening Checklist for Contraindications to 
Vaccines for Adults 
For patients: The following questions will help us determine which vaccines you may be given today. If you 
answer “yes” to any question, it does not necessarily mean you should not be vaccinated. It just means 
additional questions mustbe asked. If a question is notclear, please ask your healthcare provider to explain 
it. 
Don’t 
Yes No Know 
1.  Are you sick today?   
2.  Do you have allergies to medications, food, a vaccine component, or latex?   
3.  Have you ever had a serious reaction after receiving a vaccination? 
 

 

 

4. Do you have a long-term health problem with heart disease, lung disease, asthma, 
kidneydisease, metabolic disease (e.g., diabetes), anemia, or other blooddisorder? 
 

 

 

5.   Do you have cancer, leukemia, HIV/AIDS, or any other immune system problem? 
 

 

 

6. In the past 3 months, have you taken medications that weaken your immune system, 
such as cortisone, prednisone, other steroids, or anticancer drugs, or have you had 
radiation  treatments? 
 
 

 
 

 
 

7.  Have you had a seizure or a brain or other nervous systemproblem?   
8. During the past year, have you received a transfusion of blood or blood products, 
or been given immune (gamma) globulin or an antiviral drug? 
 

 

 

9. For women: Are you pregnant or is there a chance you could become pregnant 
during the next month? 
 

 

 

10. Have you received any vaccinations in the past 4 weeks?   
 
Form completed by: Date:   
Form reviewed by: Date:   
 
Did you bring your immunization record card with  you? yes no 
It is important for you to have a personal record of your vaccinations. If you don’t have a personal record, ask 
your healthcare provider to give you one. Keep this record in a safe place and bring it with you every time you 
seek medical care. Make sure your healthcare provider records all your vaccinations on it. 
 
Technical content reviewed by the Centers for Disease Control and Prevention 
Immunization Action Coalition Saint Paul, Minnesota • 651-647-9009 • www.immunize.org • www.vaccineinformation.org 
www.immunize.org/catg.d/p4065.pdf • Item #P4065 (1/15) 
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Information for Health Professionals about the Screening Checklist for Contraindications To Vaccines for   Adults 
Are youinterested in knowing why we included a certain question on the screening checklist? If so, read the information 
below. If you want to find out even more, consult the references listed at the bottom of this page. 
 
1. Are you sick today? [all vaccines] 
There is no evidence that acute illness reduces vaccine efficacy or increases 
vaccine adverse events (1). However, as a precaution with moderate or se- 
vere acute illness, all vaccines should be delayed until the illness has improved. 
Mild illnesses (such as upper respiratory infections or diarrhea) are NOT 
contraindicationstovaccination.Donotwithholdvaccinationifapersonistaking 
antibiotics. 
 
2. Do you have allergies to medications, food, a vaccine  component, 
or latex? [all vaccines] 
If a person has anaphylaxis after eating gelatin, do not administer MMR or 
varicella vaccine. A local reaction to a prior vaccine dose or vaccine compo- 
nents (e.g., latex) is not a contraindication to a subsequent dose or vaccine 
containing that component. For a table of vaccines supplied in vials or syringes 
that contain latex, go towww.cdc.gov/vaccines/pubs/pinkbook/downloads/ 
appendices/B/latex-table.pdf. For an extensive list of vaccine components, see 
reference 2. 
An egg-free recombinant influenza vaccine (RIV3) may be used in people 
age 18 years and older with egg allergy of any severity who have no other 
contraindications. People younger than age 18 years who have experienced 
a serious systemic or anaphylactic reaction (e.g., hives, swelling of the lips or 
tongue, acute respiratory distress, or collapse) after eating eggs can usually be 
vaccinated with inactivated influenza vaccine (IIV); consult ACIP recommenda- 
tions (seereference3). 
3. Have you ever had a serious reaction after receiving a 
vaccination? [all vaccines] 
History of anaphylactic reaction (see question 2) toa previous dose of vaccine 
or vaccine component is acontraindication for subsequent doses (1). Under 
normal circumstances, vaccines are deferred when a precaution is present. 
However, situations may arise when the benefit outweighs the risk (e.g., during 
acommunitypertussis outbreak). 
 
4. Do you have a long-term health problem with heart disease, 
lung disease, asthma, kidney disease, metabolic disease (e.g., 
diabetes), anemia, or other blood disorder? [LAIV] 
The safety of intranasal live attenuated influenza vaccine (LAIV) in people with 
these conditions has not been established. These conditions, including asthma 
in adults, should be considered precautions for the use of LAIV. 
 
5. Do you have cancer, leukemia, HIV/AIDS, or any other im- 
mune system problem? [LAIV, MMR, VAR, ZOS] 
Live virus vaccines (e.g., LAIV, measles-mumps-rubella [MMR], varicella [VAR], 
zoster [ZOS]) are usually contraindicated in immunocompromised people. 
However, there are exceptions. For example, MMR vaccine is recommended 
and varicella vaccine should be considered for adults with CD4+ T-lympho- 
cyte counts of greaterthan or equalto 200 cells/µL. Immunosuppressed people 
should not receive LAIV. For details, consult the ACIP recommendations (1, 4, 5). 
 
6. In the past 3 months, have you taken medications that 
weaken your immune system, such as cortisone, prednisone, 
other steroids, or anticancer drugs, or have you had radiation 
treatments? [LAIV, MMR, VAR, ZOS] 
Live virus vaccines (e.g., LAIV, MMR, VAR, ZOS) should be postponed until 
after chemotherapy or long-term high-dose steroid therapy has ended. For 
details and length of time to postpone, consult the ACIP statement (1, 3). To 
find specific vaccination schedules for stem cell transplant (bone marrow trans- 
plant) patients, see reference 6. LAIV can be given only to healthy non-pregnant 
people younger than age 50 years. 
7. Have you had a seizure or a brain or other nervous system 
problem? [influenza, Td/Tdap] 
Tdapis contraindicatedin peoplewhohaveahistoryof encephalopathywithin 
7 days following DTP/DTaP given before age 7 years. An unstable progressive 
neurologic problem is a precaution to the use of Tdap. For people with stable 
neurologic disorders (including seizures) unrelated to vaccination, or for people 
with a family history of seizure, vaccinate as usual. A history of Guillain-Barré 
syndrome (GBS) is a consideration with the following: 1) Td/Tdap: if GBS has 
occurredwithin 6 weeks of atetanus-containing vaccine and decision is made 
to continue vaccination, give Tdap instead of Td if no history of prior Tdap; 2) 
Influenza vaccine (IIV/LAIV): if GBS has occurred within 6 weeks of a prior in- 
fluenza vaccine, vaccinate with IIV if at high risk for severe influenza complications. 
8. During the past year, have you received a transfusion of blood 
or blood products, or been given immune (gamma) globulin or an 
antiviral drug? [LAIV, MMR, VAR] 
Certain live virus vaccines (e.g., LAIV, MMR, VAR, ZOS) may need to be 
deferred, depending on several variables. Consult the most current ACIP 
recommendations for current information on intervals between antiviral drugs, 
immune globulin or blood product administration and live virus vaccines. (1) 
9. For women: Are you pregnant or is there a chance you could 
become pregnant during the next month? [MMR, LAIV, VAR, ZOS] 
Live virus vaccines (e.g., MMR, VAR, ZOS, LAIV) are contraindicated one 
month before and during pregnancy because of the theoretical risk of virus 
transmissiontothe fetus. Sexually active women in their childbearing years 
who receive live virus vaccines should be instructed topractice careful con- 
traception for one month following receipt of the vaccine. On theoretical 
grounds, inactivated poliovirus vaccine should not be given during pregnancy; 
however, it may be given if risk of exposure is imminent and immediate pro- 
tection is needed (e.g., travel to endemic areas). Use of Td or Tdap is not 
contraindicated in pregnancy. At the provider’s discretion, either vaccine may 
be administered during the 2nd or 3rd trimester. (1, 3, 4, 5, 7, 8) 
 
10. Have you received any vaccinations in the  past  4 weeks? 
[LAIV, MMR, VAR, yellow fever] People who were given either LAIV or an in- 
jectable live virus vaccine (e.g., MMR, VAR, ZOS, yellow fever) should wait 28 
days before receiving another vaccination of this type. Inactivated vaccines may 
be given at any spacing interval if they are not administered simultaneously. 
References: 
1. CDC. General recommendations on immunization, at www.cdc.gov/vaccines/ 
pubs/acip-list.htm 
2. Table of Vaccine Components: www.cdc.gov/vaccines/pubs/pinkbook/downloads/ 
appendices/B/excipient-table-2.pdf. 
3. CDC. Prevention and control of seasonal influenza with vaccines: Recommenda- 
tions of the ACIP—2014–2015 Influenza Season at www.cdc.gov/mmwr/pdf/wk/ 
mm6332.pdf, pages 691–7. 
4. CDC. Measles, mumps, and rubella—vaccine use and strategies for elimination 
of measles, rubella, and congenital rubella syndrome and control of mumps. 
MMWR 1998; 47 (RR-8). 
5. CDC. Prevention of varicella: Recommendations of the Advisory Committee on Im- 
munization Practices. MMWR 2007; 56 (RR-4). 
6. Tomblyn M, Einsele H, et al. Guidelines for preventing infectious complications 
among hematopoietic stem cell transplant recipients: a global perspective. Biol Blood 
MarrowTransplant 15:1143–1238; 2009at www.cdc.gov/vaccines/pubs/hemato- 
cell-transplts.htm. 
7. CDC. Notice to readers: Revised ACIP recommendation for avoiding pregnancy 
after receiving a rubella-containing vaccine. MMWR 2001; 50 (49). 
8. CDC. Prevention of pertussis, tetanus, and diphtheria among pregnant and postpar- 
tumwomenandtheirinfants:RecommendationsoftheACIP.MMWR2008;57(RR-4). 
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Appendix H 
 
Educational Component #1: Post-session 
Questionnaire 
Thank you for taking a few moments of your time to complete the brief questionnaire 
below. Your honest feedback is encouraged and extremely valuable; it ensures 
successful implementation of a project that will address your needs, while also 
providing long-term benefits to both the office and its valued patients. 
 
 
 
 
, 
 
 
Please rate the following statements on the extent to which you agree or disagree: 
 
 Strongly 
Disagree 
Disagree Neutral Agree Strongly 
Agree 
 
The material presented during this session was 
educational and applicable to my job. 
     
The information increased my awareness of how 
significant the problem of suboptimal pneumococcal 
vaccination rates is. 
     
The student clearly identified the problem and 
proposed intervention for addressing the problem. 
     
I think a Standing Orders Program will help to 
increase rates of pneumococcal vaccination  amongst 
our patients 65 and older. 
     
I am confident that staff will be able to successfully 
implement a Standing Orders Program. 
     
Patients will be receptive to this project.      
 
 
1.) What, if any, are your concerns regarding the proposedintervention? 
 
 
 
 
 
 
2.) Do you feel that a Standing Orders Program will work effectively at your 
site? Why or why not? 
 
 
 
 
 
3.) Please provide any feedback that you believe will be beneficial in making 
this project a success for the staff, patients and student: 
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Appendix I 
 
Goals and Objectives of Proposed Capstone Intervention 
Goal I. Identify a multidisciplinary team within primary care to design and implement a program that 
meets both state and federal regulatory requirements and national vaccination goals.  
Objective Outcome Measures 
i. Increase staff and provider awareness of 
the significance of the problem (i.e. 
suboptimal pneumococcal vaccination 
rates among adults 65 and older) and 
justify the need for the chosen 
intervention. 
a. An educational session/practice meeting will be 
conducted within the first 1-2 weeks of the semester 
(middle to end of September).  
 
b. A post-educational session questionnaire will be 
distributed to staff to determine if the presentation 
was successful in achieving this objective.  At least 
80% of participants will provide feedback. 
a. A practice meeting will be conducted within the 
first week of student beginning final capstone 
rotation; at the close of the meeting 90% of 
participants will be educated on HCP, system and 
patient barriers previously identified by the student 
in current evidence-based research.  
ii. Increase provider and staff awareness 
of potential barriers to achieving targeted 
vaccination rates 
b. A survey will be conducted at the end of the 
meeting – at least 60% of providers and staff will 
agree that a SOP can help alleviate at least one 
barrier.  
a. 90% of the practice’s providers (MDs and NPs) 
and clinical staff will be provided a copy of the 
Immunization Action Coalition’s standing orders 
for administration of PPSV23 and PCV13 to adults.  
iii. Increase provider and staff awareness 
of recommendations and regulations 
regarding SOPs for vaccines 
b. 90% of providers and staff will provided a copy 
of the Massachusetts Department of Public Health – 
Model Standing Orders for both PPSV23 and 
PCV13.  
c. 90% of providers will be informed of the 
recommendations by Advisory Committee on 
Immunization Practices (ACIP) and Centers for 
Medicare and Medicaid on the use of SOPs. 
a. 80% of key stakeholders will attend two separate 
educational sessions between 9/9 and 11/1 that will 
address all components of objective. 
iv. Increase pertinent stakeholder’s 
knowledge of project’s key components, 
including the following secondary 
objectives: 
  
       iv-1.1 Immunization practices 
       iv-1.2HealthyPeople 2020 objectives 
       iv-1.3 CDC eligibility criteria for 
b. At the end of the in-service a post-session 
questionnaire will be distributed; at least 80% of 
attendees will complete it.  
a. An SOP will be implemented by November 2nd, 
2015.   
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PPSV23 and PCV13 vaccines 
       iv-1.4 Core concepts of disease risk 
criteria for target population 
       iv-1.5 Utilization and analysis of 
patient data in EHR  
       iv-1.6 Vaccine order procedures.  
iv. Establish, implement and evaluate a 
standing orders program that will be 
utilized and accessible by appropriate key 
stakeholders. 
b. By Spring 2016, at least 60% of providers and 
staff will express willingness to utilize SOPs in the 
future. 
 
  
 Goal II.  Ensure all eligible adults age 65 and older in primary care are effectively motivated 
and informed of current pneumococcal vaccination recommendations and provided an opportunity 
for vaccination. 
Objective Outcome Measures 
i. Establish baseline data for 
vaccination rates of patients aged 
65 and older in the practice  
a. Baseline data will be gathered and reviewed prior to the 
2015-2016 influenza season 
ii. Identify and eliminate missed 
vaccination opportunities 
a. By 10/15/15, 75% of providers will assess their 
schedule for a previous work week and identify at least 3 
patients that were due for a pneumococcal vaccine but it 
wasn’t discussed 
b. Providers will report discussing pneumococcal 
vaccination with at least 75% of eligible patients by the 
end of the 2015-2016 influenza season  
c. 60% of providers will report assessing and discussing 
vaccination status at every clinical encounter 
iii. Increase patient awareness of 
pneumococcal disease and vaccine 
availability. 
a. 90% of adult patients 65 and older or their patient 
representatives will be provided a flyer and screening tool 
on pneumococcal disease and vaccination upon check-in. 
b. Flyers will be hung in all exam rooms by the end of 
September 2015 
c. An educational poster regarding pneumococcal disease 
and vaccination will be hung in the waiting room by the 
end of September 2015 
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Goals Related to Population 
 Goal III.  Reduce overall morbidity and mortality caused by pneumococcal disease among 
adults age 65 and older in primary care. 
 
 
Objective Outcome Measures 
i. Expand immunization services  a. At least 75% of patients age 65 and older will complete 
screening and be administered a pneumococcal vaccine if 
determined to be eligible. 
ii. Increase the annual 
immunization rates of adults age 65 
and older who are vaccinated 
against pneumonia in primary care. 
a. In line with HealthyPeople 2020, a target 90% of the 
practice’s patients aged 65 and older will have received a 
pneumococcal vaccination by the end of the 2015-2016 
influenza season. 
b. Improve practice’s pneumococcal vaccine coverage by 
at least 20% before the end of the 2015-2016 influenza 
season 
